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Background
The Phase III trial of ALVAC-HIV® and AIDSVAX® B/E in
Thailand began in October 2003 and concluded in June
2009. Both vaccine candidates express HIV-1 circulating
recombinant form (CRF) 01_AE and subtype B antigens.
This study assessed whether the Phase III vaccine lots
show immunogenicity comparable to the previous Phase
I/II study of the identical immunization regimen.
Methods
A list of blinded samples from persons completing all 4
injections with either placebo or vaccine and remained
HIV negative at the end of the trial was provided. Periph-
eral blood mononuclear cells (PBMC) or plasma were
tested to CRF 01_AE and subtype B vaccine antigens in the
following validated assays: (1) Interferon-gamma (IFN-γ)
ELISpot; (2) IFN-γ/interleukin-2 intracellular cytokine
staining (ICS); (3) Binding antibody (BAb).  ELISpot and
ICS assays measured responses to Env (92TH023) and
Gag (LAI) peptide pools prior to and 6 months following
the completion of immunization.  BAb was measured
using reciprocal dilution EIA to A244 and MN gp120 and
BH10 p24 prior to and at 2 weeks following the comple-
tion of immunization.
Results
Data will be un-blinded to treatment assignment by Octo-
ber 2009. Analyses of post-injection responses to Env and
Gag by ELISpot revealed an overall frequency of 14%,
with Env responses (11%) predominating over Gag (5%).
The overall frequency of ICS responses to HIV peptides in
samples studied to date was 35% and was greater for CD4
(26%) than CD8 (9%) T cells, with responses to Env again
predominating: 26% versus 1% Gag for CD4 and 6% Env
versus 2% Gag for CD8 T cells. The frequency of BAb
responses to p24 was 37% and was identical for
CRF01_AE and MN gp120 (70%).
Conclusion
Cellular and humoral immune responses to the ALVAC-
HIV® + AIDSVAX® B/E regimen were predominantly to
HIV Env and appear similar to those seen in the earlier
Phase I/II study.  
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